Should I Buy VRAX? VRAX 2026 Analysis

Should You Buy Virax Biolabs Group Ltd (VRAX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.280

1 Day change

-1.73%

52 Week Range

2.290

Analysis Updated At

2026/01/26

Virax Biolabs Group Ltd (VRAX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows a bearish technical trend, lacks positive trading signals, has no recent news or catalysts, and is projected to decline in the short and medium term. Additionally, analysts have lowered their price target, and there is no strong financial or institutional support to justify a long-term investment at this time.

Technical Analysis

The technical indicators for VRAX are bearish. The MACD is negatively expanding, the RSI is neutral at 20.222, and the moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 0.265 and resistance at 0.376. Additionally, similar candlestick patterns suggest an 80% chance of a -4.78% drop in the next day, -13.75% in the next week, and -18.36% in the next month.

Options Data

Positive Catalysts

NULL identified. There is no recent news or significant positive developments for the stock.

Neutral/Negative Catalysts

The stock is also projected to decline in the short and medium term based on historical patterns.

Financial Performance

No financial data is available to assess the company's latest quarter performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright maintains a Buy rating but has significantly lowered the price target from $3 to $1. The company's focus on long-term projects, such as advancing ViraxImmune and launching studies, does not provide immediate value for investors.

1 Analyst Rating

Wall Street analysts forecast VRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is 1 USD with a low forecast of 1 USD and a high forecast of 1 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.290

Low

Averages

High

Current: 0.290

Low

Averages

High

H.C. Wainwright

Buy

downgrade

$3 -> $1

AI Analysis

2026-01-09

Reason

H.C. Wainwright

Price Target

$3 -> $1

AI Analysis

2026-01-09

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Virax Biolabs to $1 from $3 and keeps a Buy rating on the shares. Virax Biolabs outlined 2026 priorities focused on advancing ViraxImmune for Post-Acute Infection Syndromes, including reporting initial data from two fully enrolled U.K. studies in 2Q26 to support potential MHRA submission, launching a U.S. long COVID study with Emory University, and expanding ImmuneSelect RUO commercialization, the analyst tells investors in a research note. Recent mechanistic data show clear T-cell exhaustion and dysfunction in PAIS patients, consistent with the immune signatures ViraxImmune is designed to detect, with the company's current market value estimated at approximately $26M, the firm says.

HC Wainwright & Co.

Yi Chen

Strong Buy

Initiates

2025-03-31

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-03-31

Initiates

Strong Buy

Reason

VRAX Should I Buy

VRAX Should I Buy

Should You Buy Virax Biolabs Group Ltd (VRAX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch